i&i Bio

Investment decisions are led by Founding Partners Karel Kubias, Ivan Vohlmuth, and Tomáš Maršálek, alongside Partner Barbora Šumová. Kubias brings 20 years of life sciences executive experience, Vohlmuth has overseen over 100 investments across CEE, and Maršálek specializes in fund management and valuations. The team comprises seven professionals including an associate and an advisor.

The firm is embedded in the innovation ecosystem around the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Science, providing access to preclinical research and academic spinouts. It also scouts broadly across Europe for early-stage life science ventures, focusing on Central and Eastern Europe but open to pan-European opportunities. The portfolio includes companies from drug discovery, medtech, diagnostics, and AI verticals.

i&i Bio is structured as a Luxembourg-based venture capital fund, not a family office. The firm operates as a VC focused exclusively on early-stage life sciences, deploying a €53M fund with targeted investments between €150,000 and €2M per round. It is externally managed by a team of seven professionals including founding partners with backgrounds in pharma, private equity, and fund management.

i&i Bio primarily makes direct equity investments in early-stage life science companies. The fund deploys capital at seed, startup, and growth stages, with a sweet spot between €0.5M and €2M for follow-on rounds. It also reserves additional funding for what it calls 'unicorn' portfolio companies, indicating a co-investment or direct-investment strategy rather than a fund-of-funds approach.

The fund targets early-stage ventures from seed to growth, with a starting ticket of €150,000 for business creation and a sweet spot between €0.5M and €2M for scaling rounds. Portfolio companies include both preclinical-stage biotech startups and those advancing into clinical trials, such as Captain T Cell and T-CURX. i&i Bio also retains capacity to follow on for exceptional performers.

i&i Bio focuses exclusively on life sciences, with specific verticals including drug discovery, medtech, diagnostics, and AI-driven biotech. The firm explicitly avoids generalist tech or non-life sciences investments. Its portfolio spans drug discovery platforms, medtech devices, diagnostic tools, and AI applications for drug discovery, as reflected in companies like Antiverse, HeartBeat.bio, and Theorema.

The source of capital is not publicly disclosed by i&i Bio. The firm operates as a Luxembourg-based venture capital fund with a declared €53M fund. As an external VC, it likely draws from institutional LPs such as pension funds, family offices, or European development institutions, but no specific investors are named on the firm’s website.